11798-1-AP
antibody from Proteintech Group
Targeting: BUD31
Cwc14, EDG-2, EDG2, fSAP17, G10, YCR063W
Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 11798-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#11798-1-AP, RRID:AB_2274894
- Product name
- BUD31 antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated BUD31 antibody (Cat. #11798-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IHC, IP, WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Bud31-mediated alternative splicing is required for spermatogonial stem cell self-renewal and differentiation.
Splicing factor BUD31 promotes ovarian cancer progression through sustaining the expression of anti-apoptotic BCL2L12.
Multi-omics approach reveals posttranscriptionally regulated genes are essential for human pluripotent stem cells.
The spliceosome is a therapeutic vulnerability in MYC-driven cancer.
Qin J, Huang T, Wang Z, Zhang X, Wang J, Dang Q, Cui D, Wang X, Zhai Y, Zhao L, Lu G, Shao C, Li S, Liu H, Liu Z
Cell death and differentiation 2023 Jan;30(1):184-194
Cell death and differentiation 2023 Jan;30(1):184-194
Splicing factor BUD31 promotes ovarian cancer progression through sustaining the expression of anti-apoptotic BCL2L12.
Wang Z, Wang S, Qin J, Zhang X, Lu G, Liu H, Guo H, Wu L, Shender VO, Shao C, Kong B, Liu Z
Nature communications 2022 Oct 21;13(1):6246
Nature communications 2022 Oct 21;13(1):6246
Multi-omics approach reveals posttranscriptionally regulated genes are essential for human pluripotent stem cells.
Iwasaki M, Kawahara Y, Okubo C, Yamakawa T, Nakamura M, Tabata T, Nishi Y, Narita M, Ohta A, Saito H, Yamamoto T, Nakagawa M, Yamanaka S, Takahashi K
iScience 2022 May 20;25(5):104289
iScience 2022 May 20;25(5):104289
The spliceosome is a therapeutic vulnerability in MYC-driven cancer.
Hsu TY, Simon LM, Neill NJ, Marcotte R, Sayad A, Bland CS, Echeverria GV, Sun T, Kurley SJ, Tyagi S, Karlin KL, Dominguez-VidaƱa R, Hartman JD, Renwick A, Scorsone K, Bernardi RJ, Skinner SO, Jain A, Orellana M, Lagisetti C, Golding I, Jung SY, Neilson JR, Zhang XH, Cooper TA, Webb TR, Neel BG, Shaw CA, Westbrook TF
Nature 2015 Sep 17;525(7569):384-8
Nature 2015 Sep 17;525(7569):384-8
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- mouse brain tissue were subjected to SDS PAGE followed by western blot with 11798-1-AP(BUD31 antibody) at dilution of 1:2000
- Sample type
- tissue
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The BUD31 antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human BUD31. This antibody recognizes human, mouse, rat antigen. The BUD31 antibody has been validated for the following applications: ELISA, WB, IHC analysis.